Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

25, 37.5 and 50 mg/day, oral, administered on an outpatient basis in two different dosing regimens: schedule 2/1 (2 weeks on, 1 week off) and schedule 4/2 (4 weeks on, 2 weeks off)

60, 75, and 100 mg/m2 docetaxel administered every 21 days as a 1-hr IV infusion